Bluejay Diagnostics
BJDX
Market cap $1.78M

0.0662 USD

-0.0078

10.54%

At close Nov 15, 4:00 PM EST

After hours

0.0672

+0.0010

1.51%

1 day

-10.54%

5 days

-27.89%

1 month

-39.54%

3 months

-78.37%

6 months

-98.42%

Year to date

-99.30%

1 year

-99.76%

5 years

-99.99%

10 years

-99.99%

About: Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Employees: 10

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

160% more funds holding

Funds holding: 5 [Q2] → 13 (+8) [Q3]

9% more capital invested

Capital invested by funds: $119K [Q2] → $129K (+$10.4K) [Q3]

24.13% less ownership

Funds ownership: 30.27% [Q2] → 6.14% (-24.13%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BJDX.

See Analyst Rankings

Financial journalist opinion

Bluejay Diagnostics Announces Reverse Stock Split

ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, “BJDX.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633509.

Bluejay Diagnostics Announces Reverse Stock Split

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants have an exercise price of $1.30 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance.

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.30 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The closing of the offering is expected to occur on or about January 2, 2024, subject to the satisfaction of customary closing conditions.

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

See News Rankings

Charts implemented using Lightweight Charts™